Shearman & Sterling represented Quest Diagnostics Incorporated in connection with an underwritten public offering of 15,377,600 shares of Quest’s common stock held by GlaxoSmithKline plc., its largest stockholder. Concurrently with the public offering, Quest repurchased the 15,377,551 shares of its common stock from GlaxoSmithKline plc. Following this offering and the repurchase, GlaxoSmithKline plc no longer holds common stock of Quest. Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC acted as joint bookrunners for the offering. Quest Diagnostics is the world’s leading provider of diagnostic testing, information and services.

The Shearman & Sterling team included partners Stephen Giove (New York-Capital Markets) and Lona Nallengara (New York-Capital Markets); counsel Ferdinand Erker (New York-Capital Markets); associates Shihani Soysa (New York-Capital Markets) and Jennifer A. Val (New York-Capital Markets); and legal assistant Brian Shea (New York-Capital Markets).